1
|
Louie S, Heidersbach A, Blanco N, Haley B, Rose CM, Liu PS, Yim M, Tang D, Lam C, Sandoval WN, Shaw D, Snedecor B, Misaghi S. Endothelial intercellular cell adhesion molecule 1 contributes to cell aggregate formation in CHO cells cultured in serum‐free media. Biotechnol Prog 2020; 36:e2951. [DOI: 10.1002/btpr.2951] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 11/14/2019] [Accepted: 12/11/2019] [Indexed: 11/09/2022]
Affiliation(s)
- Salina Louie
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Amy Heidersbach
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Noelia Blanco
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Benjamin Haley
- Molecular Biology DepartmentGenentech, Inc. South San Francisco California
| | - Christopher M. Rose
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Peter S. Liu
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - Mandy Yim
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Danming Tang
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Cynthia Lam
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Wendy N. Sandoval
- Microchemistry Proteomic and Lipidomic (MPL) DepartmentGenentech, Inc. South San Francisco California
| | - David Shaw
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Brad Snedecor
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| | - Shahram Misaghi
- Cell Culture DepartmentGenentech, Inc. South San Francisco California
| |
Collapse
|
2
|
Loyet KM, Hass PE, Sandoval WN, Morando A, Liu P, Shatz W, Dickmann L, Kenrick M, Good J, Davancaze T, Morimoto AM, Kelley RF, Scheer JM. In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm 2018; 16:86-95. [PMID: 30444371 DOI: 10.1021/acs.molpharmaceut.8b00871] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
The collection of aqueous humor (phase 1 b/2 Mahalo study) from patients dosed intravitreally with anti-factor D (AFD; FCFD4514S, lampalizumab), a humanized antibody fragment previously under investigation to treat geographic atrophy (GA) secondary to age-related macular degeneration, presented a unique opportunity to examine AFD properties in clinical samples. We investigated AFD stability and target-binding characteristics to set up strategies for engineering and evaluating optimized molecules that enable less frequent dosing. Two variants, AFD.v8 and AFD.v14, were evaluated as alternatives to AFD for longer-acting treatments. Mass spectrometry, surface plasmon resonance, and immunoassay were used to assess AFD stability and binding activity in aqueous humor samples from Mahalo patients. In vitro stability and binding activity of AFD, AFD.v8, and AFD.v14 were assessed in human vitreous humor versus buffer at 37 °C over 16 weeks and in vivo in rabbits over 28 days along with pharmacokinetic determinations. In human aqueous humor, AFD specific binding was >85% through 30 days, and deamidation was <3% through 60 days, consistent with the AFD stability and binding activity in vitreous humor from humans in vitro and rabbits in vivo. Target binding, stability, and rabbit pharmacokinetic parameters of AFD.v8 and AFD.v14 were similar to those of AFD. Physiological stability and activity of AFD translated across in vitro and in vivo studies in humans and rabbits. The two variants AFD.v8 and AFD.v14 demonstrated comparable potency and pharmacokinetics. These findings, along with previously demonstrated improved solubility of AFD.v8 and AFD.v14, provide proof-of-concept for developing other similar long-acting therapeutic variants.
Collapse
Affiliation(s)
- Kelly M Loyet
- Department of Biochemical and Cellular Pharmacology , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Philip E Hass
- Department of Protein Chemistry , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Wendy N Sandoval
- Department of Microchemistry, Proteomics, & Lipidomics , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Ashley Morando
- Department of Biochemical and Cellular Pharmacology , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Peter Liu
- Department of Microchemistry, Proteomics, & Lipidomics , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Whitney Shatz
- Department of Protein Chemistry , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Leslie Dickmann
- Department of Preclinical and Translational Pharmacokinetics , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Margaret Kenrick
- Department of Preclinical and Translational Pharmacokinetics , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Jeremy Good
- Department of Assay Development and Technology , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Teresa Davancaze
- Department of Assay Development and Technology , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Alyssa M Morimoto
- Department of Assay Development and Technology , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Robert F Kelley
- Department of Drug Delivery , Genentech, Inc. , South San Francisco , California 94080 , United States
| | - Justin M Scheer
- Department of Protein Chemistry , Genentech, Inc. , South San Francisco , California 94080 , United States
| |
Collapse
|
3
|
Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, Liu PS, Bheddah S, Tao J, Lill JR, Hongo JA, Davis D, Kirkpatrick DS, Polakis P, Costa M. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One 2011; 6:e22595. [PMID: 21799911 PMCID: PMC3143158 DOI: 10.1371/journal.pone.0022595] [Citation(s) in RCA: 154] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Accepted: 06/24/2011] [Indexed: 12/24/2022] Open
Abstract
Canonical Wnt signaling is controlled intracellularly by the level of β-catenin protein, which is dependent on Axin scaffolding of a complex that phosphorylates β-catenin to target it for ubiquitylation and proteasomal degradation. This function of Axin is counteracted through relocalization of Axin protein to the Wnt receptor complex to allow for ligand-activated Wnt signaling. AXIN1 and AXIN2 protein levels are regulated by tankyrase-mediated poly(ADP-ribosyl)ation (PARsylation), which destabilizes Axin and promotes signaling. Mechanistically, how tankyrase limits Axin protein accumulation, and how tankyrase levels and activity are regulated for this function, are currently under investigation. By RNAi screening, we identified the RNF146 RING-type ubiquitin E3 ligase as a positive regulator of Wnt signaling that operates with tankyrase to maintain low steady-state levels of Axin proteins. RNF146 also destabilizes tankyrases TNKS1 and TNKS2 proteins and, in a reciprocal relationship, tankyrase activity reduces RNF146 protein levels. We show that RNF146, tankyrase, and Axin form a protein complex, and that RNF146 mediates ubiquitylation of all three proteins to target them for proteasomal degradation. RNF146 is a cytoplasmic protein that also prevents tankyrase protein aggregation at a centrosomal location. Tankyrase auto-PARsylation and PARsylation of Axin is known to lead to proteasome-mediated degradation of these proteins, and we demonstrate that, through ubiquitylation, RNF146 mediates this process to regulate Wnt signaling.
Collapse
Affiliation(s)
- Marinella G. Callow
- Department of Cancer Targets, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Hoanh Tran
- Department of Cancer Targets, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Lilian Phu
- Department of Protein Chemistry, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Ted Lau
- Department of Cancer Targets, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - James Lee
- Department of Discovery Oncology, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Wendy N. Sandoval
- Department of Protein Chemistry, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Peter S. Liu
- Department of Protein Chemistry, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Sheila Bheddah
- Department of Research Pathology, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Janet Tao
- Department of Research Pathology, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Jennie R. Lill
- Department of Protein Chemistry, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Jo-Anne Hongo
- Department of Antibody Engineering, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - David Davis
- Department of Discovery Oncology, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Donald S. Kirkpatrick
- Department of Protein Chemistry, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Paul Polakis
- Department of Cancer Targets, Genentech Research and Early Development, South San Francisco, California, United States of America
| | - Mike Costa
- Department of Cancer Targets, Genentech Research and Early Development, South San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|
4
|
Wilson DG, Phamluong K, Li L, Sun M, Cao TC, Liu PS, Modrusan Z, Sandoval WN, Rangell L, Carano RA, Peterson AS, Solloway MJ. Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse. J Cell Biol 2011. [PMCID: PMC3144406 DOI: 10.1083/jcb.2010071621942c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Wilson DG, Phamluong K, Li L, Sun M, Cao TC, Liu PS, Modrusan Z, Sandoval WN, Rangell L, Carano RAD, Peterson AS, Solloway MJ. Global defects in collagen secretion in a Mia3/TANGO1 knockout mouse. ACTA ACUST UNITED AC 2011; 193:935-51. [PMID: 21606205 PMCID: PMC3105544 DOI: 10.1083/jcb.201007162] [Citation(s) in RCA: 134] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Mia3’s contribution to protein secretion is broader than previously realized—its absence impairs collagen deposition and normal development of cartilage and bone. Melanoma inhibitory activity member 3 (MIA3/TANGO1) is an evolutionarily conserved endoplasmic reticulum resident transmembrane protein. Recent in vitro studies have shown that it is required for the loading of collagen VII, but not collagen I, into COPII-coated transport vesicles. In this paper, we show that mice lacking Mia3 are defective for the secretion of numerous collagens, including collagens I, II, III, IV, VII, and IX, from chondrocytes, fibroblasts, endothelial cells, and mural cells. Collagen deposition by these cell types is abnormal, and extracellular matrix composition is compromised. These changes are associated with intracellular accumulation of collagen and the induction of a strong unfolded protein response, primarily within the developing skeleton. Chondrocyte maturation and bone mineralization are severely compromised in Mia3-null embryos, leading to dwarfism and neonatal lethality. Thus, Mia3’s role in protein secretion is much broader than previously realized, and it may, in fact, be required for the efficient secretion of all collagen molecules in higher organisms.
Collapse
Affiliation(s)
- Deanna G Wilson
- Department of Molecular Biology, Genentech, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Lu Y, Xiang H, Liu P, Tong RR, Watts RJ, Koch AW, Sandoval WN, Damico LA, Wong WL, Meng YG. Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration. MAbs 2009; 1:364-9. [PMID: 20068394 DOI: 10.4161/mabs.1.4.8885] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Neuropilin-1 (NRP1) acts as a co-receptor for class 3 semaphorins and vascular endothelial growth factor and is an attractive angiogenesis target for cancer therapy. In addition to the transmembrane form, naturally occurring soluble NRP1 proteins containing part of the extracellular domain have been identified in tissues and a cell line. We developed ELISAs to study the existence of circulating NRP1 and to quantify it in serum. As measured by ELISAs, circulating NRP1 levels in mice, rats, monkeys and humans were 427 +/- 77, 20 +/- 3, 288 +/- 86 and 322 +/- 82 ng/ml (mean +/- standard deviation; n > or = 10), respectively. Anti-NRP1(B), a human monoclonal antibody, has been selected from a synthetic phage library. A 4-fold increase in circulating NRP1 was observed in mice receiving a single dose of 10 mg/kg anti-NRP1(B) antibody. In rats and monkeys receiving single injections of anti-NRP1(B) at different dose levels, higher doses of antibody resulted in greater and more prolonged increases in circulating NRP1. Maximum increases were 56- and 7-fold for rats and monkeys receiving 50 mg/kg anti-NRP1(B), respectively. In addition to the soluble NRP1 isoforms, for the first time, a approximately 120 kDa circulating NRP1 protein containing the complete extracellular domain was detected in serum by western blot and mass spectrometry analysis. This protein increased more than the putative soluble NRP1 bands in anti-NRP1(B) treated mouse, rat and monkey sera compared with untreated controls, suggesting that anti-NRP1(B) induced membrane NRP1 shedding.
Collapse
Affiliation(s)
- Yanmei Lu
- Department of Assay and Automation Technology, Genentech Inc., South San Francisco, CA 94080, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Sandoval WN, Pham VC, Lill JR. Recent developments in microwave-assisted protein chemistries – can this be integrated into the drug discovery and validation process? Drug Discov Today 2008; 13:1075-81. [DOI: 10.1016/j.drudis.2008.08.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2008] [Revised: 08/08/2008] [Accepted: 08/18/2008] [Indexed: 10/21/2022]
|
8
|
Abstract
State-of-the-art proteomic analysis has recently undergone a rapid evolution; with more high-throughput analytical instrumentation and informatic tools available, sample preparation is becoming one of the rate-limiting steps in protein characterization workflows. Recently several protocols have appeared in the literature that employ microwave irradiation as a tool for the preparation of biological samples for subsequent mass spectrometric characterization. Techniques for microwave-assisted bio-catalyzed reactions (including sample reduction and alkylation, enzymatic and chemical digestion, removal and analysis of post-translational modifications and characterization of enzymes and protein-interaction sites) are described. This review summarizes the various approaches undertaken, instrumentation employed, and reduction in overall experimental time observed when microwave assistance is applied.
Collapse
Affiliation(s)
- Jennie R Lill
- Protein Chemistry Department, Genentech Inc, South San Francisco, CA 94080, USA.
| | | | | | | | | |
Collapse
|
9
|
Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci U S A 2007; 104:5306-11. [PMID: 17372204 PMCID: PMC1828710 DOI: 10.1073/pnas.0700184104] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Hepatocyte growth factor (HGF), the ligand for the receptor tyrosine kinase Met, is secreted as single chain pro-HGF that lacks signaling activity. Pro-HGF acquires functional competence upon cleavage between R494 and V495, generating a disulfide-linked alpha/beta-heterodimer, where the beta-chain of HGF (HGF beta) has a serine protease fold that lacks enzymatic activity. We show that, like serine proteases, insertion of the newly formed N terminus in the beta-chain is critical for activity, here by allosterically stabilizing interactions with Met. The HGF beta crystal structure shows that V495 inserts into the "activation pocket" near the Met binding site where the positively charged N terminus forms a salt bridge with the negatively charged D672, and the V495 side chain has hydrophobic interactions with main- and side-chain residues. Full-length two-chain HGF mutants designed to interrupt these interactions (D672N, V495G, V495A, G498I, and G498V) displayed <10% activity in Met receptor phosphorylation, cell migration, and proliferation assays. Impaired signaling of full-length mutants correlated with >50-fold decreases in Met binding of the low-affinity HGF beta domain alone bearing the same mutations and further correlated with impaired N-terminal insertion. Because high-affinity binding resides in the HGF alpha-chain, full-length mutants maintained normal Met binding and efficiently inhibited HGF-mediated Met activation. Conversion of HGF from agonist to antagonist was achieved by as little as removal of two methyl groups (V495A) or a single charge (D672N). Thus, although serine proteases and HGF have quite distinct functions in proteolysis and Met signal transduction, respectively, they share a similar activation mechanism.
Collapse
Affiliation(s)
- Daniel Kirchhofer
- Departments of *Protein Engineering
- To whom correspondence may be addressed. E-mail: or
| | | | | | | | | | | | | | - John Ridgway
- Tumor Biology and Angiogenesis, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080
| | | | - Robert A. Lazarus
- Departments of *Protein Engineering
- To whom correspondence may be addressed. E-mail: or
| |
Collapse
|
10
|
Pham V, Henzel WJ, Arnott D, Hymowitz S, Sandoval WN, Truong BT, Lowman H, Lill JR. De novo proteomic sequencing of a monoclonal antibody raised against OX40 ligand. Anal Biochem 2006; 352:77-86. [PMID: 16545334 DOI: 10.1016/j.ab.2006.02.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2005] [Revised: 01/05/2006] [Accepted: 02/01/2006] [Indexed: 11/24/2022]
Abstract
De novo sequencing of a full-length monoclonal antibody raised against OX40 ligand is described. Using a combination of overlapping complementary proteolytic and chemical digestions, with analysis by mass spectrometry and Edman degradation, both the heavy and light chains were fully sequenced. Particular attention was paid to those modifications that could be susceptible to degradation in the complementarity determining region and Fc region. An overview of the protocol is described, and suggestions for improvements to aid in such sequencing projects in the future are discussed.
Collapse
Affiliation(s)
- Victoria Pham
- Department of Protein Chemistry, Genentech, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | |
Collapse
|